Eleven New Drugs Filed In EU; Sipavibart & Dorocubicel Win Fast-Track Status

 
• By Neena Brizmohun

AstraZeneca’s sipavibart for preventing COVID-19 in the highly vulnerable population of immunocompromised patients is among the latest drugs that the European Medicines Agency has started to review for potential pan-EU marketing authorization.

The EMA has started reviewing a new batch of drug marketing applications • Source: Shutterstock

More from Europe

More from Geography